Previous Close | 254.76 |
Open | 259.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 259.00 - 259.00 |
52 Week Range | 243.42 - 354.00 |
Volume | |
Avg. Volume | 213 |
Market Cap | 188.574B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 16.63 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 10.86 (4.19%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.